Zoladex (Goserelin Implant) for Breast Cancer

Overview
Zoladex is approved by the U.S. Food and Drug Administration (FDA) for the palliative treatment of advanced breast cancer in premenopausal and perimenopausal women, according to the prescribing information. This treatment is used when other options may not be suitable or as an additional therapy to help manage symptoms and slow disease progression. Zoladex should not be used by individuals who are pregnant or planning to become pregnant due to potential risks to the fetus. A person must confirm that they are not pregnant before beginning treatment. Zoladex's generic name is goserelin implant.

Zoladex is a type of gonadotropin-releasing hormone (GnRH) agonist. It works by reducing the production of estrogen, a hormone that can fuel the growth of certain types of breast cancer. By lowering estrogen levels, Zoladex helps to slow the progression of the cancer and manage associated symptoms.

How do I take it?
Prescribing information states that Zoladex is administered as a subcutaneous (under the skin) implant. It is typically injected into the lower part of the abdomen every 28 days. The duration of treatment may vary based on the individual’s specific condition and response to therapy. Zoladex should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Zoladex for treatment of breast cancer include hot flashes, headache, sweating, acne, mood changes (such as emotional instability and depression), decreased libido (sexual desire), breast atrophy (shrinkage), oily skin, and swelling in the extremities (arms and legs).

Rare but serious side effects may include allergic reactions (hypersensitivity), hyperglycemia (increased blood sugar levels), and an increased risk of developing diabetes. Some individuals may experience cardiovascular issues such as an elevated risk of heart attack, stroke, or sudden cardiac death. In addition, prolonged use may affect bone density, increasing the risk of osteoporosis. Zoladex may also prolong the QT interval (a measure of heart rhythm), which could increase the risk of abnormal heartbeats. Injection site injuries and the potential for a tumor flare (worsening of symptoms) may also occur during initial treatment. Depression may occur or worsen in some individuals, requiring close monitoring.

For more information about this treatment, visit:
Label: Zoladex — Goserelin Implant — DailyMed

Goserelin Implant — MedlinePlus